Monoclonal gammopathy of undetermined significance medical therapy
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance medical therapy On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance medical therapy |
|
FDA on Monoclonal gammopathy of undetermined significance medical therapy |
|
on Monoclonal gammopathy of undetermined significance medical therapy |
|
Monoclonal gammopathy of undetermined significance medical therapy in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance medical therapy |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
There is no specific treatment for monoclonal gammopathy of undetermined significance ; the mainstay of therapy is supportive care, keep an eye and delay the progression to other plasma dyscrasias. Trials using lenalidomide and bisphosphonates are been conducted to determine whether they decrease they progression of the disease both for MGUS and multiple myeloma
Medical Therapy
There is no specific treatment for monoclonal gammopathy of undetermined significance ; the mainstay of therapy is supportive care, keep an eye and delay the progression to other plasma dyscrasias.[1] Trials using lenalidomide and bisphosphonates are been run to determine whether they decrease they progression of the disease both for MGUS and multiple myeloma.[2][3][4] Vitamin D and calcium can be given as anti-resorptive therapy.[5]
References
- ↑ Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E (October 2009). "UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)". Br. J. Haematol. 147 (1): 22–42. doi:10.1111/j.1365-2141.2009.07807.x. PMID 19673884.
- ↑ Pozzi S, Raje N (2011). "The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future". Oncologist. 16 (5): 651–62. doi:10.1634/theoncologist.2010-0225. PMC 3228190. PMID 21493759.
- ↑ Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF (August 2013). "Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma". N. Engl. J. Med. 369 (5): 438–47. doi:10.1056/NEJMoa1300439. PMID 23902483.
- ↑ Mahindra A, Pozzi S, Raje N (September 2012). "Clinical trials of bisphosphonates in multiple myeloma". Clin Adv Hematol Oncol. 10 (9): 582–7. PMID 23073123.
- ↑ Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA (July 2010). "Monoclonal gammopathy of undetermined significance: a consensus statement". Br. J. Haematol. 150 (1): 28–38. doi:10.1111/j.1365-2141.2010.08207.x. PMID 20507313.